TerminatedNCT01184443
Evaluation of the Efficacy and Safety of Olanzapine for Eating disorders in Children and Adolescents
Medication studyAges 11–17Canada
Understand this study
Who could participate?
Listed age limits: 11 years to 17 years.
- Listed locations
- OttawaSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateAugust 2010
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 38
- Sponsor
- Children's Hospital of Eastern Ontario
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Canada
- Age range
- From 11 Years to 17 Years
- Official registry ID
- NCT01184443
- Official title
Show the full official title
Evaluation of the Efficacy and Safety of Olanzapine as an Adjunctive Treatment for Anorexia Nervosa in Children and Adolescents: An Open-label Trial
Recruitment & locations
TerminatedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Ottawa
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Children's Hospital of Eastern Ontario, a hospital or academic medical center.
Does this study involve medication?
Yes. The study involves medication, including Olanzapine.
Who can participate?
Listed age limits: 11 years to 17 years.
Is this study still recruiting?
The registry lists this study as terminated.
